Investor worries over Zhejiang Tianyu Pharmaceutical's slowi...

Investor worries over Zhejiang Tianyu Pharmaceutical's slowing revenue could explain its low P/S ratio. The company needs notable financial uplift to justify ratio increase. Its lackluster future prospects compared to industry may clarify its current P/S status.